To advance the use of CCT as a molecular target for neuroblastoma, we tested a CCT inhibitor developed by the Khaled lab, CT20p, and demonstrated its efficacy in killing neuroblastoma cells. This evidence concerns the gene FLVCR2 and neuroblastoma.